Dave Vetterlein, PhD

Dave Vetterlein, PhD | CMO Arrangements, Process Development, GMP Manufacturing

David Vetterlein, PhD, brings over 25 years of biotechnology experience in the areas of bioprocessing and protein manufacturing. Most recently, Dr. Vetterlein worked in numerous capacities at ICOS Corporation. At ICOS, he built a clinical manufacturing facility and developed the infrastructure needed to support a pipeline of biologic products at a production scale of up to 3,000L. This included hiring and staff management for process engineering, project management, upstream and downstream process development and cGMP manufacturing through Phase III development in preparation for commercial launch. Additionally, Dr. Vetterlein established a very successful contract manufacturing business at ICOS, completing more than 25 different projects from yeast, CHO and E.coli origin and developing many novel biologic manufacturing processes and characterization methods. In 2007, the ICOS biologics division was sold to CMC Biopharma of Copenhagen and Dr. Vetterlein became Chief Science Officer, focusing on process troubleshooting, originating new process technologies, and establishing the conceptual design for a large-scale commercial manufacturing facility.

Prior to ICOS, Dr. Vetterlein worked at Genentech, Inc. for 10 years as a Senior Scientist where he developed processes for manufacturing of vaccines, antibodies and other proteins. He is a member of the Amgen Bioprocess Advisory Board at Keck Graduate Institute of Applied Life Sciences in Claremont, CA and in 2009 he became an adjunct faculty member. Dr. Vetterlein earned in PhD in Biology (Biochemistry) from the University of California at Santa Barbara, where he utilized biophysical methods to study the kinetic and allosteric properties of a cytoplasmic enzyme.

"Cori Gorman has an extraordinarily high level of expertise, which was one of the critical factors in choosing her for this. When things come up again, she is the person I will go to."

- Senior scientist at a biotechnology company.

An independent third party conducted a quality survey for DNA Bridges,Inc. The third party, in association with Dunn and Bradstreet, interviewed several clients. All clients stated that the costs met expectations and projects were competed on time.